Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Not Applicable
- Conditions
- Solid Tumor.
- Registration Number
- NCT02220556
- Lead Sponsor
- Institut Curie
- Brief Summary
Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
- 18 years old or more
- Performance status from 0 to 4
- Patient treated followed for histologically confirmed solid tumor type of any of these localization : breast, prostate, uterus, ovary, colon, lung, head and neck, melanoma.
- Informed consent form signed.
Read More
Exclusion Criteria
- Patient with history of other invasive cancer within 5 years.
- Patient treated for any non-invasive cancer
- Patient individually deprived of liberty or placed under the authority of a tutor
- Geographical condition potentially preventing compliance with the study protocol.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method CTC, CEC or ctDNA incidence 3 years number of CTC or CEC in 7.5ml of blood
- Secondary Outcome Measures
Name Time Method CTC and CEC molecular characterization 3 years This outcome is self-explanatory.
Circulating tumor DNA (ctDNA) detection and quantification 3 years plasma mutation detection (number of copy)
Trial Locations
- Locations (2)
Institut Mutualiste Montsouris
🇫🇷Paris, France
Institut Curie
🇫🇷Saint-Cloud, France